Med2Date — Clinical Guidelines
Home Geriatric Medicine Urinary Incontinence and Lower Urinary Tract Symptoms

Urinary Incontinence and Lower Urinary Tract Symptoms

Last updated 1 Jun 2026 · Geriatric medicine

📋 Key Information Summary

📋
  • Urinary incontinence affects up to 38% of Australian women and 14% of men over 60; it is common but not inevitable with ageing and warrants systematic assessment.
  • Classify incontinence as urge (detrusor overactivity), stress (urethral hypermobility/intrinsic sphincter deficiency), overflow (detrusor underactivity/bladder outlet obstruction), or functional (mobility/cognitive barriers to toileting).
  • Always search for reversible causes using the DIAPPERS mnemonic (Delirium, Atrophic urethritis, Pharmaceuticals, Psychological, Excess urine output, Restricted mobility, Stool impaction) before initiating definitive treatment.
  • A structured bladder diary (minimum 3 days) is the single most useful initial investigation and guides type-specific management.
  • Post-void residual (PVR) volume measurement is essential when overflow incontinence is suspected; PVR >100 mL (or >200 mL in men) warrants urological referral.
  • First-line treatment for urge incontinence is bladder training ± pelvic floor muscle training; pharmacotherapy with antimuscarinics (oxybutynin, solifenacin) or β₃-agonists (mirabegron) is second-line.
  • Stress incontinence responds best to supervised pelvic floor exercises; duloxetine (off-label) may be used when surgery is not appropriate.
  • Overflow incontinence requires treatment of the underlying cause (e.g., α-blocker for BPH, clean intermittent catheterisation for detrusor underactivity).
  • Functional incontinence is managed by addressing contributing factors: mobility aids, timed/prompted voiding, environmental modification, and continence product support.
  • Conduct a comprehensive medication review at every encounter — diuretics, anticholinergics, α-agonists, opioids, sedatives, calcium-channel blockers and SGLT2 inhibitors are common contributors.
  • Topical vaginal oestrogen is effective for urge symptoms in postmenopausal women and is listed on the PBS (MBS item 58117 for GP Management Plan if relevant).
  • Anticholinergic burden must be assessed before prescribing antimuscarinics, particularly in older adults with cognitive impairment — consider mirabegron as a non-anticholinergic alternative.
  • Surgical options (mid-urethral sling, colposuspension, intradetrusor onabotulinum toxin A, sacral neuromodulation) are reserved for refractory cases after conservative measures have failed.
  • Aboriginal and Torres Strait Islander peoples experience higher rates of urinary tract infections and incontinence-related morbidity; culturally safe, trauma-informed continence assessments and access to The National Continence Helpline (1800 33 00 66) are essential.

Introduction & Australian Epidemiology

Urinary incontinence (UI) — defined by the International Continence Society (ICS) as the complaint of any involuntary leakage of urine — is one of the most prevalent yet under-reported chronic conditions in Australia. It affects an estimated 4.8 million Australians, with prevalence rising sharply after age 60. Despite this burden, fewer than half of those affected seek medical attention due to embarrassment, misconceptions about normal ageing, and lack of awareness that effective treatments exist.

Continence care in the geriatric population must adopt a holistic, goal-directed approach that considers mobility, cognition, current medications, urinary symptoms, bowel function, and the individual patient's goals and preferences. Involuntary urine loss is not an inevitable consequence of ageing; rather, it is a treatable condition that significantly impairs quality of life, increases falls risk (particularly nocturia-related falls), causes social isolation, skin breakdown, urinary tract infections, and is a leading cause of residential aged-care admission.

The Australian Institute of Health and Welfare (AIHW) reports that UI is the most common condition managed in residential aged-care facilities, affecting up to 70% of residents. The Continence Foundation of Australia estimates the annual cost of managing incontinence at over .7 billion, including direct healthcare costs, continence products, carer burden, and lost productivity. The National Continence Helpline (1800 33 00 66) provides free, confidential advice and is an important resource for patients and clinicians alike.

Type Prevalence in Older Adults Female : Male Ratio Characteristics
Urge incontinence 40–50% of all UI 2 : 1 Sudden urgency, frequency, nocturia; detrusor overactivity
Stress incontinence 30–40% of all UI 8 : 1 Leakage with cough, sneeze, exertion; urethral hypermobility or intrinsic sphincter deficiency
Overflow incontinence 10–15% of all UI 1 : 5 Continuous or dribbling; bladder over-distension; detrusor underactivity or outlet obstruction
Functional incontinence 10–20% of all UI 2 : 1 Normal bladder function but inability to toilet due to mobility, cognition, or environmental barriers
Mixed incontinence Up to 30% of cases 5 : 1 Combination of urge + stress; manage the predominant component first
⚠️
Red flags requiring urgent assessment: Acute urinary retention, new-onset incontinence with haematuria, suspected cauda equina syndrome (saddle anaesthesia, bowel dysfunction, bilateral leg weakness), recurrent UTI in men, or rapidly progressive symptoms suggestive of malignancy. Refer urgently to urology or emergency as appropriate.

Urge, Stress, Overflow and Functional Incontinence

Urge Incontinence (Urgency UI)

Urge incontinence is the most common subtype in older adults and results from involuntary detrusor muscle contractions (detrusor overactivity). Patients describe a sudden, compelling desire to void that is difficult to defer, often accompanied by frequency (>8 voids/day), nocturia (≥2 episodes/night), and involuntary leakage before reaching the toilet. Idiopathic detrusor overactivity is the usual cause in elderly women, while neurogenic detrusor overactivity (stroke, Parkinson's disease, multiple sclerosis, spinal cord injury) should be considered in men and atypical presentations.

💡
Overactive bladder (OAB) syndrome is characterised by urgency, usually with frequency and nocturia, with or without urge incontinence. OAB-dry (no leakage) and OAB-wet (with leakage) are distinguished. Not all OAB is incontinence, but all urge incontinence falls within the OAB spectrum.

Stress Incontinence (Stress UI)

Stress incontinence is the involuntary leakage on effort, exertion, sneezing, or coughing. In women, it arises from two main mechanisms:

  • Urethral hypermobility — pelvic floor weakness leads to descent of the bladder neck during increases in intra-abdominal pressure, resulting in an open proximal urethra.
  • Intrinsic sphincter deficiency (ISD) — loss of urethral mucosal coaptation and smooth/skeletal muscle tone, often seen after pelvic surgery or radiotherapy.

In men, stress incontinence is most commonly post-prostatectomy (radical prostatectomy or transurethral resection of prostate). It is uncommon in men without prior pelvic surgery or radiation.

Overflow Incontinence

Overflow incontinence occurs when the bladder cannot empty adequately, leading to chronic urinary retention with continuous or intermittent dribbling. Key causes include:

  • Bladder outlet obstruction (BOO) — benign prostatic hyperplasia (BPH) is the most common cause in older men; pelvic organ prolapse or urethral stricture in women.
  • Detrusor underactivity (DU) — impaired bladder contractility from diabetes (autonomic neuropathy), neurological disease, or idiopathic ageing-related changes. Common in older men and women alike.
🚨
Acute urinary retention is a medical emergency. Presenting with suprapubic pain, inability to void, and a palpable/tender bladder, it requires immediate catheterisation (12–14 Fr urethral or suprapubic if expected prolonged). Avoid clamping in acute settings. Refer to urology.

Functional Incontinence

Functional incontinence describes involuntary urine loss attributable to factors external to the lower urinary tract — primarily impaired mobility, cognitive impairment, or environmental barriers (e.g., call bell out of reach, bed too high, inaccessible toilet). The bladder itself is functionally intact. It is the predominant type in advanced dementia and is extremely common in residential aged-care settings. Management is directed at the underlying barrier rather than the bladder.

Mild
Mild LUTS / Early Incontinence
Frequency <10 voids/day; nocturia 1–2 episodes; occasional small-volume leaks; pad use ≤1/day; minimal lifestyle impact.
Setting: General practice — conservative management, bladder diary, lifestyle advice
Moderate
Moderate LUTS / Established Incontinence
Frequency 10–15 voids/day; nocturia 2–4 episodes; daily leakage affecting social activity; pad use 2–3/day; may require pharmacotherapy.
Setting: General practice ± continence specialist — bladder training + pharmacotherapy
Severe
Severe LUTS / Refractory Incontinence
Constant or near-constant leakage; frequent pad changes; skin breakdown; significant QoL impairment; behavioural/pharmacological failure.
Setting: Continence service / Urology — specialist assessment, urodynamics, surgical consideration

Reversible Causes and Medication Review

Before initiating type-specific treatment, clinicians must identify and address reversible contributing factors. The mnemonic DIAPPERS provides a systematic approach:

Factor Examples Management
Delirium Acute confusional state from infection, metabolic disturbance, medication Treat underlying cause; incontinence usually resolves with cognition
Infection Symptomatic UTI (dysuria, frequency, suprapubic pain) — note: asymptomatic bacteriuria should NOT be treated in the elderly Urine MCS → targeted antibiotics per eTG; short course (3–5 days) in older adults
Atrophic urethritis/vaginitis Postmenopausal oestrogen deficiency causing urethral mucosal thinning Topical vaginal oestrogen (oestriol cream or estradiol pessary); PBS-listed
Pharmaceuticals See medication review table below Dose adjustment, timing change, substitution, or deprescribing
Psychological Depression (apathy, immobility), anxiety (frequency), psychotic disorders Treat mood disorder; consider impact of psychotropics on bladder
Excess urine output Polyuria (diabetes mellitus/incipidus), nocturnal polyuria, excess fluid intake, caffeine, alcohol, SGLT2 inhibitors, diuretics Optimise glycaemia; review fluid intake; consider diuretic timing (morning dose)
Restricted mobility Arthritis, Parkinson's disease, post-stroke, frailty, post-hip fracture Mobility aids, physiotherapy, commode chair at bedside, toileting schedule
Stool impaction Faecal impaction causing bladder compression and overflow; overflow incontinence mimic Disimpaction, bowel management programme, adequate fibre/fluids

Medication Review: Drugs Commonly Contributing to Incontinence or LUTS

Drug Class Examples Effect on Bladder Action
Loop diuretics Furosemide, bumetanide Polyuria, urgency, frequency Morning dosing; avoid evening doses
SGLT2 inhibitors Dapagliflozin, empagliflozin Osmotic diuresis, glycosuria, genital candidiasis Counsel patients; assess contribution to UI
Anticholinergics (CNS) Oxybutynin, TCAs, antihistamines, antipsychotics Urinary retention (paradoxically can worsen overflow) Measure PVR; deprescribe where possible
α-Adrenergic agonists Pseudoephedrine, midodrine Bladder outlet obstruction (increased urethral tone) Avoid in men with BPH; consider alternative decongestants
Calcium-channel blockers Nifedipine, verapamil, diltiazem Detrusor relaxation → impaired contractility → retention Measure PVR; consider alternative antihypertensives
Opioids Codeine, tramadol, oxycodone, morphine Detrusor underactivity, urinary retention, constipation Minimise dose; concurrent bowel management
Sedatives/hypnotics Benzodiazepines, z-drugs, quetiapine Functional incontinence (impaired mobility, sedation, nocturnal awareness) Deprescribe; address sleep hygiene
ACE inhibitors/ARBs Perindopril, irbesartan Chronic cough (ACE-I) → stress incontinence exacerbation Switch ACE-I to ARB if troublesome cough
⚠️
Anticholinergic burden in older adults: The Anticholinergic Cognitive Burden (ACB) scale should be used to quantify total anticholinergic load. Scores ≥3 are associated with increased risk of cognitive decline, falls, and delirium. Avoid concurrent anticholinergic medications in patients already prescribed antimuscarinics for urge incontinence — consider mirabegron as a non-anticholinergic alternative.

Bladder Diary and Investigations

A systematic approach to investigation begins with the bladder diary, supplemented by focused physical examination, urine testing, and selected imaging and functional studies as indicated by the clinical pattern.

Bladder Diary (Minimum 3-Day Micturition Chart)

The bladder diary is the cornerstone of UI assessment. The patient records all fluid intake and voided volumes over at least 72 hours, including:

  • Time and volume of each void (using a measured jug)
  • Time and volume of fluid intake (type of fluid)
  • Episodes of urgency and incontinence (with provoking factors)
  • Pad use and degree of wetness
  • Nocturnal voids and sleep quality
  • Bowel movements and stool consistency (Bristol Stool Chart)

Key parameters derived from the diary: 24-hour urine volume, maximum voided volume, average voided volume, daytime frequency, nocturia frequency, functional bladder capacity, and incontinence episodes per day.

Physical Examination

  • Abdominal examination: Palpable bladder (retention), masses, ascites
  • Pelvic examination (women): Atrophic vaginitis, pelvic organ prolapse (cystocele, uterine prolapse), cough stress test (positive = visible leakage with cough)
  • Digital rectal examination (men): Prostate size, consistency, nodules (malignancy screen), faecal impaction
  • Neurological examination: Lower limb sensation, reflexes (S2–S4), anal tone, perineal sensation (saddle area)
  • Mobility and cognitive assessment: Timed Up and Go test, Mini-Mental State Examination or MoCA if functional incontinence suspected

Investigations

Essential Urine microscopy, culture and sensitivity (MCS) Rule out symptomatic UTI. Do NOT treat asymptomatic bacteriuria in older adults (MBS item 69315 for urine culture if indicated).
Essential Post-void residual (PVR) volume — ultrasound bladder scanner or catheterisation Normal <50 mL; 50–100 mL equivocal; >100 mL significant (women) or >200 mL (men) suggests overflow/retention. Repeat measurement recommended. MBS item 55053.
Available Serum creatinine, eGFR, HbA1c, fasting glucose Screen for diabetes (polyuria), chronic kidney disease (impaired concentrating ability); routine biochemistry panel.
Available Renal tract ultrasound Hydronephrosis, renal calculi, bladder wall thickness, post-void volume. Indicated if PVR elevated, recurrent UTI, or suspected obstruction. MBS item 55110.
Available Serum prostate-specific antigen (PSA) In men with LUTS where prostate malignancy is clinically suspected (after informed consent and shared decision-making). Not a screening test for incontinence.
Specialist Urodynamic studies (multichannel cystometry, pressure-flow study) Gold standard for confirming detrusor overactivity, detrusor underactivity, or bladder outlet obstruction. Indicated when conservative management fails, before surgery, or in complex/refractory cases. Available at major public hospitals and private urology practices.
Specialist Cystoscopy Haematuria screen, urethral stricture assessment, bladder pathology. Indicated if haematuria, recurrent infection, or suspected bladder pathology.
Referral Pad weight testing (quantification of leakage) 1-hour or 24-hour pad test to objectively quantify leakage severity; useful for baseline measurement and monitoring treatment response.
💡
When to refer to a continence specialist or urologist: Failed 8–12 weeks of conservative management; suspected overflow or neurogenic incontinence; PVR >200 mL; recurrent UTI; haematuria; suspected pelvic organ prolapse ≥stage 2; consideration of surgery; complex mixed incontinence; or diagnostic uncertainty.

Behavioural, Pharmacological and Surgical Options

Behavioural and Conservative Therapies (First-Line for All Types)

Behavioural interventions are the foundation of incontinence management and should be trialled for a minimum of 8–12 weeks before escalating to pharmacological or surgical options.

1
Bladder Training
Structured schedule of voiding at fixed intervals, progressively increasing the interval by 15–30 minutes every 1–2 weeks until a target of 3–4 hours between voids is achieved. Effective for urge and functional incontinence. Duration: 6–12 weeks minimum.
2
Pelvic Floor Muscle Training (PFMT)
Supervised exercise programme (8 contractions × 3 sessions/day, hold 6–8 seconds, 3-month minimum). Best evidence for stress incontinence (NNT 4). Should be supervised by a continence physiotherapist (MBS item 10950 for allied health under GP Management Plan). Also benefits urge incontinence.
3
Prompted Voiding and Timed Voiding
For functional incontinence in dementia/cognitive impairment. Carers prompt the patient to use the toilet at regular intervals (every 2–3 hours during the day). Evidence shows reduction in incontinence episodes by 30–50% in residential care settings.
4
Fluid and Dietary Modification
Target 1.5–2 L/day fluid intake (not excess). Reduce caffeine (≤2 cups/day), alcohol, and artificial sweeteners. Avoid fluid restriction (concentrated urine worsens urgency and UTI risk). Evening fluid restriction 2 hours before bed to reduce nocturia.
5
Weight Management and Constipation
Weight loss of 5–10% reduces stress incontinence episodes by 50% in overweight women. Treat constipation aggressively (fibre, fluids, laxatives) — faecal loading impairs bladder function. Regular bowel programme.
6
Continence Products and Skin Care
Pads (absorbent products), catheters (indwelling or intermittent), urinals, bedpans. Products available via the Continence Aids Payment Scheme (CAPS) — Federal Government provides up to 9.60/year (indexed). Apply barrier cream to prevent incontinence-associated dermatitis.

Pharmacological Management

Urge Incontinence — Antimuscarinic Agents

Antimuscarinics (anticholinergics) are second-line for urge incontinence after behavioural therapy. They block M3 muscarinic receptors on the detrusor muscle, reducing involuntary contractions. Efficacy is moderate (NNT ≈ 7 for cure, NNH ≈ 12 for dry mouth).

💊
Oxybutynin
Ditropan® · Kentera® (patch) · Antimuscarinic
Adult dose 2.5 mg PO BD–TDS, titrate to 5 mg TDS (max 5 mg TDS in elderly); transdermal patch 3.9 mg/day twice weekly
Paediatric dose ≥5 years: 0.2 mg/kg PO BD–TDS (max 5 mg TDS)
Renal adjustment eGFR <30: use with caution, start at lowest dose
Key ADRs Dry mouth (common), constipation, blurred vision, confusion (highest anticholinergic burden of all OAB drugs — avoid extended-release in elderly)
PBS status ✔ PBS General Benefit
💊
Solifenacin
Vesicare® · Antimuscarinic (M3 selective)
Adult dose 5 mg PO once daily, titrate to 10 mg once daily after 4 weeks if tolerated
Renal adjustment eGFR <30: max 5 mg/day
Hepatic adjustment Child-Pugh A: max 5 mg/day; Child-Pugh B–C: avoid
Key ADRs Dry mouth, constipation, QT prolongation (rare); lower anticholinergic burden than oxybutynin
PBS status Authority Required (initial treatment of urge incontinence after bladder training failure)
💊
Trospium
Regurin® · Antimuscarinic (quaternary ammonium)
Adult dose 20 mg PO BD (before meals)
Renal adjustment eGFR <30: 20 mg once daily or avoid
Key ADRs Does not cross blood-brain barrier → lower CNS effects; dry mouth, constipation still occur
PBS status Authority Required

Urge Incontinence — β₃-Adrenoceptor Agonist (Non-Anticholinergic Option)

💊
Mirabegron
Betmiga® · β₃-adrenoceptor agonist
Adult dose 25 mg PO once daily (extended-release); may increase to 50 mg once daily after 4–8 weeks
Renal adjustment eGFR 15–29: max 25 mg/day; eGFR <15: not recommended
Hepatic adjustment Child-Pugh A: max 25 mg/day; Child-Pugh B–C: not recommended
Key advantages No anticholinergic effects — preferred in elderly with cognitive impairment or high ACB score; no dry mouth or constipation; monitor blood pressure (hypertension) and heart rate
PBS status Authority Required (failure of or intolerance to antimuscarinic therapy)

Stress Incontinence — Pharmacological Adjunct

💊
Duloxetine
Cymbalta® · SNRI (off-label for UI)
Adult dose 20 mg PO BD for 2 weeks, then increase to 40 mg PO BD
Renal adjustment eGFR <30: avoid
Key ADRs Nausea (common, usually transient), dry mouth, constipation, dizziness, fatigue; serotonin syndrome risk with other serotonergic agents
PBS status ✔ PBS General Benefit (for major depressive disorder — off-label for UI)
💊
Topical Oestrogen
Ovestin® (estriol) · Vagifem® (estradiol) · Oestrogen
Adult dose Ovestin cream: 0.5 mg intravaginally nightly for 2 weeks, then twice weekly maintenance; Vagifem pessary: 10 mcg intravaginally nightly for 2 weeks, then twice weekly
Indication Atrophic urethritis/vaginitis contributing to urge and stress symptoms; vaginal dryness, recurrent UTI in postmenopausal women
Key ADRs Vaginal irritation (uncommon); minimal systemic absorption at recommended doses
PBS status ✔ PBS General Benefit

Overflow Incontinence — Pharmacological Options

💊
Tamsulosin
Flomaxtra® · α₁A-adrenoceptor blocker
Adult dose 400 mcg PO once daily (after food)
Indication Bladder outlet obstruction secondary to BPH; improves urine flow and reduces PVR
Key ADRs Orthostatic hypotension, dizziness, retrograde ejaculation; intraoperative floppy iris syndrome (notify ophthalmologist before cataract surgery)
PBS status ✔ PBS General Benefit
💊
Dutasteride
Avodart® · 5α-reductase inhibitor
Adult dose 500 mcg PO once daily
Indication BPH with enlarged prostate (>30 mL); reduces prostate volume over 3–6 months; reduces risk of urinary retention and need for surgery
Key ADRs Erectile dysfunction, decreased libido, gynaecomastia; reduces PSA by ~50% (adjust interpretation); teratogenic — women must not handle crushed tablets
PBS status Authority Required

Surgical Options (Third-Line — After Conservative and Pharmacological Failure)

Procedure Indication Key Details Success Rate
Mid-urethral sling (MUS) — retropubic or transobturator Stress UI in women (first-line surgical) Day procedure; tension-free polypropylene tape; retro pubic (TVT) or transobturator (TOT) approach. Complications: mesh erosion (1–3%), voiding dysfunction, groin pain (TOT). 80–90% at 1 year; 70–80% at 5 years
Burch colposuspension Stress UI (alternative to MUS or concurrent with prolapse repair) Open or laparoscopic; sutures elevate bladder neck. Longer recovery; durable long-term results. 85–90% at 1 year; 70% at 10 years
Intradetrusor onabotulinum toxin A (Botox®) Refractory urge UI / neurogenic detrusor overactivity 100–200 units injected into detrusor via cystoscopy (day procedure). Duration: 6–12 months; repeat injections. Risk of UTI (25%) and urinary retention (5–10%, may need CIC). PBS Authority for neurogenic OAB. 70–80% improvement in neurogenic DO; 50–60% in idiopathic OAB
Sacral neuromodulation (SNM) — InterStim® Refractory urge UI, non-obstructive urinary retention, faecal incontinence Implanted electrode at S3 foramen; staged procedure (test phase 1–2 weeks then permanent implant if ≥50% improvement). MRI-conditional with newer devices. 50–70% sustained improvement at 5 years
Percutaneous tibial nerve stimulation (PTNS) Refractory urge UI (non-invasive alternative to SNM) Weekly 30-minute sessions for 12 weeks, then monthly maintenance. Needle electrode at medial ankle (posterior tibial nerve S2–S4). Available in select Australian centres. 50–60% improvement
Artificial urinary sphincter (AUS) — AMS 800 Severe stress UI (post-prostatectomy in men; ISD in women — rare) Cuff around urethra, pump in scrotum/labia, reservoir in Retzius space. Requires manual dexterity to operate. Revision rate 25–30% at 10 years. 70–90% social continence at 5 years
TURP / HoLEP BPH with BOO causing overflow incontinence/retention Transurethral resection or holmium laser enucleation of prostate. Indicated when medical therapy fails. MBS items 36900, 37210. Complications: TUR syndrome (rare), retrograde ejaculation (70%), bleeding, infection. 85–95% improvement in flow rate; 2–5% new stress UI
⚠️
Mid-urethral mesh slings — TGA safety advisory: The TGA has strengthened regulation of urogynaecological mesh devices. Patients must receive comprehensive informed consent regarding risks of chronic pain, mesh erosion, dyspareunia, and the need for potential revision surgery. Discuss alternative options. The Australian Pelvic Floor Surgery Registry tracks outcomes for all mesh implant procedures.

Special Populations

👴

Elderly / Frail

  • Incontinence is common but never normal — always investigate reversible causes.
  • Assess anticholinergic burden (ACB scale) before prescribing antimuscarinics; prefer mirabegron in patients with cognitive impairment.
  • Oxybutynin — highest CNS penetration and ACB; avoid in dementia. Use trospium or mirabegron as safer alternatives.
  • Prompted voiding and timed voiding are evidence-based for functional incontinence in residential aged care.
  • Nocturia increases falls risk — nocturnal pad use is safer than toileting in the dark for high-falls-risk individuals.
  • Assess for concurrent faecal incontinence — up to 50% coexist in residential care.
👶

Paediatric Considerations

  • Daytime continence expected by age 4; nighttime continence by age 5–6.
  • Daytime incontinence in a previously dry child warrants investigation for UTI, constipation, diabetes, or neurological pathology.
  • Nocturnal enuresis (age >5) — first-line: bedwetting alarm (evidence-based, NNT 3); second-line: desmopressin 120–240 mcg sublingual at bedtime (PBS authority required).
  • Oxybutynin is the only antimuscarinic with paediatric PBS approval (≥5 years) for neurogenic bladder / OAB.
  • Constipation is the single most important reversible cause of childhood incontinence — always assess and treat.
🫘

Renal Impairment

  • Reduced renal concentrating ability → polyuria and nocturia; manage fluid intake and underlying CKD.
  • Dose-adjust antimuscarinics: solifenacin max 5 mg/day (eGFR <30); mirabegron max 25 mg/day (eGFR 15–29).
  • Oxybutynin and trospium — use with caution in severe CKD; no specific dose recommendation but start low.
  • Nocturnal polyuria (≥33% of 24-hour output at night) — consider desmopressin (off-label in adults; monitor sodium carefully in elderly).
  • Monitor for urinary retention with antimuscarinics; check PVR regularly.
🫁

Hepatic Impairment

  • Solifenacin: max 5 mg/day in Child-Pugh A; avoid in Child-Pugh B–C.
  • Mirabegron: max 25 mg/day in Child-Pugh A; avoid in Child-Pugh B–C.
  • Oxybutynin, trospium: no specific hepatic dose adjustment, but use cautiously in severe hepatic disease.
  • Ascites may compress the bladder and mimic overflow; assess PVR in this population.
🛡️

Immunocompromised

  • Higher risk of complicated UTI — investigate any new onset incontinence in immunocompromised patients.
  • Spinal cord injury → neurogenic bladder with high risk of autonomic dysreflexia during bladder distension (medical emergency).
  • Diabetic cystopathy: autonomic neuropathy → insidious onset of overflow incontinence; screen PVR in long-standing diabetes.
  • Multiple sclerosis: neurogenic detrusor overactivity common; antimuscarinics are first-line; intradetrusor botulinum toxin for refractory cases.
  • Catheter-associated UTI is the most common nosocomial infection — minimise catheter use and duration; consider suprapubic catheter if long-term drainage needed.
🤰

Pregnancy and Postnatal

  • UI in pregnancy is predominantly stress type (30–50% of pregnancies); usually resolves postpartum.
  • PFMT during pregnancy reduces antenatal and postnatal incontinence (evidence from Cochrane review).
  • Pharmacotherapy is generally avoided in pregnancy; conservative management is first-line.
  • Persistent UI at 6 weeks postpartum warrants referral to continence physiotherapist (MBS item 81310).
  • Obstetric risk factors: instrumental delivery, prolonged second stage, third/fourth-degree perineal tears, macrosomia, high BMI.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health
Higher prevalence
Aboriginal and Torres Strait Islander Australians experience higher rates of urinary incontinence-related conditions including recurrent UTI, renal disease (3.6× higher rate of dialysis), diabetes-related cystopathy, and chronic constipation. Incontinence contributes significantly to skin breakdown, social isolation, and reduced quality of life in First Nations communities.
Remote access barriers
Continence specialist services, urodynamics, and urological surgical options are largely unavailable in remote and very remote communities. Patients may require travel of hundreds of kilometres and temporary relocation for specialist assessment. Telehealth continence consultations (MBS items 99200–99215) can provide initial assessment and follow-up. The RFDS and Royal Flying Doctor Service provide retrieval for acute urinary retention.
Cultural safety
Continence assessment is an intimate topic; clinicians must be sensitive to cultural norms around discussing bodily functions, particularly with Elders. Gender-concordant clinicians (female clinicians for female patients and vice versa) are strongly preferred for pelvic examination and continence history-taking. Use locally preferred language and engage Aboriginal Health Workers/Practitioners as cultural brokers. "Sorry Business" and community obligations may affect appointment attendance — offer flexible scheduling.
Continence aids access
The Continence Aids Payment Scheme (CAPS) provides up to 9.60/year for eligible individuals. In remote communities, supply chain issues may cause intermittent stockouts of continence products. Aboriginal Community Controlled Health Organisations (ACCHOs) can assist with CAPS applications and bulk product orders. The National Continence Helpline (1800 33 00 66) provides culturally appropriate advice and can connect patients with local services.
Multimorbidity context
Aboriginal and Torres Strait Islander peoples carry a higher burden of comorbid conditions that contribute to UI: type 2 diabetes (3–4× higher prevalence), chronic kidney disease, rheumatic heart disease (diuretic use), and neurological complications of diabetes. Management must be integrated with existing chronic disease management programmes, particularly GP Management Plans (MBS item 721) and Team Care Arrangements (MBS item 723).
Health literacy and housing
Overcrowded housing in many remote communities reduces privacy for toileting, bladder diary completion, and continence product management. Health promotion materials should use pictorial formats and avoid medical jargon. Community-based continence education programmes delivered by Aboriginal Health Workers improve identification and early management. Environmental factors (functional toilets, proximity of toilet to sleeping areas) significantly influence functional incontinence prevalence.

📚 References

  1. 1. Abrams P, Cardozo L, Wagg A, Wein A, editors. Incontinence: 7th International Consultation on Incontinence. Bristol: International Continence Society; 2023.
  2. 2. Australian Institute of Health and Welfare. Incontinence in Australia. AIHW Cat. No. AUS 192. Canberra: AIHW; 2019.
  3. 3. National Institute for Health and Care Excellence. Urinary incontinence and pelvic organ prolapse in women: management. NICE Guideline NG123. London: NICE; 2019 (updated 2023).
  4. 4. Qaseem A, Dallas P, Forciea MA, Starkey M, Denberg TD, for the Clinical Guidelines Committee of the American College of Physicians. Nonsurgical management of urinary incontinence in women: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014;161(6):429–440.
  5. 5. Continence Foundation of Australia. National Continence Helpline and information resources. Available at: www.continence.org.au. Accessed June 2025.
  6. 6. Wagg AS, Newman DK, Kuchel GA, et al. Systematic review of conservative management of overactive bladder in older adults. J Am Geriatr Soc. 2021;69(8):2284–2301.
  7. 7. Dumoulin C, Cacciari LP, Hay-Smith EJC. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev. 2018;10:CD005654.
  8. 8. U.S. Food and Drug Administration. Considerations about surgical mesh for SUI — Updated safety communication. Silver Spring, MD: FDA; 2019.
  9. 9. Khandelwal C, Kistler C. Diagnosis of urinary incontinence. Am Fam Physician. 2013;87(8):543–550.
  10. 10. Burt J, Millard T, Scott J, Grant R. Frequency-volume charts in the evaluation of urinary incontinence. BJU Int. 2019;123(4):557–561.
  11. 11. Salisbury Memorial Hospital and British Geriatrics Society. Guidelines for the management of urinary incontinence in frail older people. London: BGS; 2020.
  12. 12. Royal Australian College of General Practitioners. Management of urinary incontinence in primary care. East Melbourne: RACGP; 2022.
  13. 13. Siriwardana A, Qu LG, Lawrentschuk N. Urinary incontinence in Aboriginal and Torres Strait Islander peoples: a scoping review. Aust N Z J Public Health. 2023;47(2):100026.
  14. 14. Healthdirect Australia. Continence Aids Payment Scheme (CAPS). Canberra: Department of Health and Aged Care; 2024.
for PBS scripts. Utilise ACCHS pharmacies and Remote Area Aboriginal Health Worker programs for medication supply in remote areas. Avoid initiating benzodiazepines; support holistic pain management including community-based exercise programs.
Preventive health
Promote bone health: encourage vitamin D supplementation (1000 IU daily in deficient individuals), smoking cessation support, reduction of alcohol intake, and weight-bearing exercise. MBS Item 715 health checks provide a structured opportunity to assess bone health, screen for osteoporosis risk factors, and discuss musculoskeletal health in a culturally safe context.

Quick Reference: Differential Diagnosis at a Glance

Costovertebral dysfunction
Paracetamol ± NSAID; manual therapy
2–6 weeks
Provocable on palpation; no red flags
Thoracic compression fracture
Paracetamol; ± calcitonin; DXA + osteoporosis Rx
6–12 weeks healing
Elderly; osteoporosis; acute onset
ACS (posterior MI)
Aspirin 300 mg, GTN, heparin; urgent PCI
Time-critical
ECG, troponin; CV risk factors
Aortic dissection
IV labetalol; urgent CT aortogram; surgery (Type A)
Time-critical
Tearing pain; BP differential >20 mmHg
Vertebral osteomyelitis
IV antibiotics (vancomycin + ceftriaxone initially); ID consult
6 weeks IV antibiotics
Fever, elevated CRP, IV drug use
Biliary colic / cholecystitis
Paracetamol ± morphine; lap cholecystectomy
Surgical within 72 h (cholecystitis)
RUQ/infrascapular; post-prandial; RUQ US

📚 References

  1. 1. Briggs AM, Smith AJ, Straker LM, Bragge P. Thoracic spine pain in the general population: prevalence, incidence and associated factors in children, adolescents and adults. A systematic review. BMC Musculoskelet Disord. 2009;10:77.
  2. 2. National Health and Medical Research Council (NHMRC). Evidence-based management of acute musculoskeletal pain. Canberra: NHMRC; 2003 (updated 2020).
  3. 3. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Summary report 2023. Canberra: AIHW; 2023.
  4. 4. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268(6):760–765.
  5. 5. Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. Europ Spine J. 2018;27(1):60–75.
  6. 6. Erwin WM, Jackson PC, Homonko DA. Innervation of the human costovertebral joint: implications for clinical back pain syndromes. J Manipulative Physiol Ther. 2000;23(6):395–403.
  7. 7. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 9th edn. Melbourne: RACGP; 2018 (updated 2023).
  8. 8. Hirsch JA, Singh V, Falco FJE, et al. Thoracic facet joint interventions. Pain Physician. 2016;19(4):E581–E593.
  9. 9. Erwin WM, Jackson PC. The costovertebral joint: anatomy, biomechanics, and clinical significance in thoracic back pain syndromes. J Can Chiropr Assoc. 2003;47(2):112–120.
  10. 10. Strayer RJ, Gunnerson JM, Brown LH, et al. Aortic dissection: clinical features, diagnosis, and management. Aust Crit Care. 2019;32(2):144–153.
  11. 11. Ombregt L. A system of orthopaedic medicine. 3rd edn. Edinburgh: Churchill Livingstone Elsevier; 2013. Chapter 18: Thoracic spine.
  12. 12. Lin CC, Chen KH, Li DM, et al. Characteristics and outcomes of patients presenting with thoracic back pain to the emergency department. Emerg Med Australas. 2020;32(5):805–811.
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).